不同药物对精神分裂症患者生活质量与认知功能的影响

目的:调查不同药物对精神分裂症患者生活质量及认知功能的影响。方法:选取精神分裂症患者216人,随机分成四组,分别给予奥氮平(A组)、阿立哌唑(B组)、利培酮(C组)、氯丙嗪(D组)治疗8周,采用PANSS、TESS、CGI、QOL-100量表评定,并进行P300认知测试。结果:氯丙嗪组不良反应最大,利培酮组女性患者发生溢乳现象;PANSS减分率A、C、B三组无统计学差异,D组低于其它三组,有统计学差异(P<0.05),B组阴性症状减分率明显高于其它组(P<0.05);氯丙嗪对总体生活质量的改善差于其它三种药物(P<0.05),在生理状态方面,B、D组明显优于A组和C组(P<0.05)。四组患者治疗8周时,P300潜伏期明显缩短(P<0.05),A、B、C组之间比较无统计学差异(P>0.05),D组与其他组比较缩短程度最小。结论:新型抗精神病药物不良反应更小,在改善生活质量、认知功能方面疗效更好,阿立哌唑在新型抗精神病药物中的性价比较高。

Effects of different drugs on quality of life and cognitive function for schizophrenic patients

Objective：To explore effects of different drugs on quality of life and cognitive function for schizophrenic patients. Methods ：216 schizophrenic patients were randomly divided into Olanzapine treated group （A group）, Aripiprazole treated group （B group）, Risperidone treated group （C group） and Chlorpromazine treated group （D group） , wherein the cases were treated with the four drugs for 8 weeks. Positive and negative symptom scale （PANSS） , treatment emergent symptom scale （TESS） , clinical global im- pression scale （CGI） and quality of life-100 （QOL-100） were used to access, and P300 cognitive test was also performed. Results： D group had the most severe side effects, whereas the female patients in C group showed galactorrhea. There were no differences in PANSS reduction rate among A, B, and C groups, while that of D group was lower that those of the three groups （P〈0.05）, and the differences were significant. The deduction rate of the negative symptoms of B group was higher than those of the other groups （P〈0. 05 ）. The improvement of the overall quality of life of D group was worse than those of the other groups （P〈0.05）. The physiological statuses of B and D group were much better than those of A and C group （P〈0.05）. 8 weeks after the treatment, the latency of P300 was obviously shortened （ P〈0.05）, and there were no significant differences among A, B, and C groups ; further, The shortening de- gree of B group was the lowest. Conclusions： The new type antipsychotic drugs has smaller side effects and are better in the improve- ment of the quality of life and cognitive function, wherein aripiprazole has a higher cost performance.